

Mexico

Population 2015

127 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	2.6 (2.6–2.7)	2.1 (2–2.1)
Mortality (HIV+TB only)	0.51 (0.03–1.7)	0.4 (0.02–1.3)
Incidence (includes HIV+TB)	27 (22–32)	21 (17–25)
Incidence (HIV+TB only)	3 (1.9–4.3)	2.3 (1.5–3.4)
Incidence (MDR/RR-TB)**	0.91 (0.75–1.1)	0.72 (0.59–0.87)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	1.2 (0.64–1.7)	9 (6–12)	10 (6.6–14)
Males	1.3 (0.84–1.7)	15 (12–18)	16 (12–20)
Total	2.4 (1.8–3.1)	24 (21–27)	27 (22–32)

TB case notifications, 2015

Total cases notified	22 294
Total new and relapse	21 600
- % tested with rapid diagnostics at time of diagnosis	1%
- % with known HIV status	89%
- % pulmonary	81%
- % bacteriologically confirmed among pulmonary	83%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	81% (68–99)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.12 (0.08–0.16)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	2 188	11%
- on antiretroviral therapy	2 120	97%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			610 (540–670)
Estimated % of TB cases with MDR/RR-TB	2.6% (2.3–2.9)	11% (9.2–13)	
% notified tested for rifampicin resistance	2%	35%	1 072
MDR/RR-TB cases tested for resistance to second-line drugs			51
Laboratory-confirmed cases		MDR/RR-TB: 158, XDR-TB: 2	
Patients started on treatment ****		MDR/RR-TB: 146, XDR-TB: 5	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	80%	21 193
Previously treated cases, excluding relapse, registered in 2014	53%	685
HIV-positive TB cases, all types, registered in 2014	48%	1 318
MDR/RR-TB cases started on second-line treatment in 2013	60%	167
XDR-TB cases started on second-line treatment in 2013	75%	4

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	19%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2016

National TB budget (US\$ millions)	19
Funding source: 100% domestic, 0% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically